Switch To RItuXimab in MS extension
Switch To RItuXimab in MS extension
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
The primary endpoint is
Other measures (1)
The secondary endpoints are:
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: A subject will be eligible for inclusion in this extension study if all of the following criteria apply: Exclusion: A subject will not be eligible for inclusion in this study if any of the following criteria applies:
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To evaluate the feasability and safety of switching from injectible MS treatments to Mabthera in stable relapsing remitting multiple sclerosis (RRMS).
Loading reviews and guidelines…
Related trials
- A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogeni
Phase 2 · Not yet recruiting
Still running
- Switch to Ofatumumab and Level of Immunoglobulins
Recruiting
Still running
- Non-interventional Study of Subcutaneous Ocrelizumab in Persons With R
Recruiting
Still running
- The HIt HArd and hiT Early in Multiple Sclerosis Trial
Phase 2 · Recruiting
Still running
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Mult
Recruiting
Still running
- Study to Assess Effects of Ublituximab in Pediatric Participants With
Phase 2 / Phase 3 · Recruiting
Still running
History
Started
Aug 2013